New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
Key Highlights
- ➤EVX-01 induced neoantigen-specific T cells detected directly ex vivo
- ➤AI-Immunology predictions significantly associated with actual T-cell responses, p<0.001
- ➤89% of EVX-01 neoantigen targets triggered tumor-specific immune responses
- ➤Phase 2 ORR reached 75%, with 12 of 16 patients responding
- ➤Three-year follow-up showed sustained T-cell and clinical responses
Expert Statements
Birgitte Rønø, CSO and COO of Evaxion
“It is exciting to announce yet another set of new and promising data providing insights into the magnitude, quality and systemic impact of EVX-01-induced immunity in advanced melanoma. The data provide a clear demonstration of the very strong immune responses induced by EVX-01 and also validates our AI-Immunology™ platform further. We are looking forward to sharing and discussing this data with both scientific stakeholders and potential business partners at the important SITC meeting”
* Detection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responses * Data further underlines the strong predictive performance of Evaxion’s AI-Immunology™ platform * The new biomarker data supplements recently published three-year data showing 89% vaccine target precision and sustained T-cell and clinical responses COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).
The data demonstrate potent EVX-01 induced immune responses and further underline the strong predictive performance of Evaxion’s AI-Immunology™ platform. It will be presented in both an oral and a poster session today and tomorrow respectively at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona.
Get started
Create a free account to read the full story.